| Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ... Science 348 (6230), 124-128, 2015 | 8287 | 2015 |
| Genetic basis for clinical response to CTLA-4 blockade in melanoma A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ... New England Journal of Medicine 371 (23), 2189-2199, 2014 | 4595 | 2014 |
| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016 | 3074 | 2016 |
| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 2017 | 2018 |
| Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses KB Chiappinelli, PL Strissel, A Desrichard, H Li, C Henke, B Akman, ... Cell 162 (5), 974-986, 2015 | 1817 | 2015 |
| Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633-641, 2018 | 1282 | 2018 |
| Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer VP Balachandran, M Łuksza, JN Zhao, V Makarov, JA Moral, R Remark, ... Nature 551 (7681), 512-516, 2017 | 1048 | 2017 |
| Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts SA Quezada, TR Simpson, KS Peggs, T Merghoub, J Vider, X Fan, ... Journal of Experimental Medicine 207 (3), 637-650, 2010 | 1019 | 2010 |
| Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ... Cancer cell 33 (5), 843-852. e4, 2018 | 965 | 2018 |
| Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for immunotherapy of cancer 8 (1), 2020 | 872 | 2020 |
| Chromatin states define tumour-specific T cell dysfunction and reprogramming M Philip, L Fairchild, L Sun, EL Horste, S Camara, M Shakiba, AC Scott, ... Nature 545 (7655), 452-456, 2017 | 859 | 2017 |
| Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells O De Henau, M Rausch, D Winkler, LF Campesato, C Liu, DH Cymerman, ... Nature 539 (7629), 443-447, 2016 | 799 | 2016 |
| Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy D Zamarin, RB Holmgaard, SK Subudhi, JS Park, M Mansour, P Palese, ... Science translational medicine 6 (226), 226ra32-226ra32, 2014 | 786 | 2014 |
| Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer JC Osorio, A Ni, JE Chaft, R Pollina, MK Kasler, D Stephens, C Rodriguez, ... Annals of Oncology 28 (3), 583-589, 2017 | 626 | 2017 |
| A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ... Nature 551 (7681), 517-520, 2017 | 624 | 2017 |
| Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ... Cancer cell 22 (5), 668-682, 2012 | 605 | 2012 |
| Emerging concepts for immune checkpoint blockade-based combination therapies R Zappasodi, T Merghoub, JD Wolchok Cancer cell 33 (4), 581-598, 2018 | 545 | 2018 |
| Role of the proto-oncogene Pokemon in cellular transformation and ARF repression T Maeda, RM Hobbs, T Merghoub, I Guernah, A Zelent, C Cordon-Cardo, ... Nature 433 (7023), 278-285, 2005 | 528 | 2005 |
| Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways L Kraehenbuehl, CH Weng, S Eghbali, JD Wolchok, T Merghoub Nature reviews Clinical oncology 19 (1), 37-50, 2022 | 510 | 2022 |
| Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner RB Holmgaard, D Zamarin, Y Li, B Gasmi, DH Munn, JP Allison, ... Cell reports 13 (2), 412-424, 2015 | 477 | 2015 |
